Immupharma welcomes its COO Dr. Tim Franklin to the Board of Directors

– UK, London –  ImmuPharma PLC (LON: IMM | EBR: ALIMM), the specialist drug discovery and development company, today announced the appointment of COO  Dr. Tim Franklin to its Board of Directors.

“It is a pleasure to welcome Tim onto the Board of Directors. Tim has made an invaluable contribution to ImmuPharma over the last three years. During this time, he played a key role in negotiations, which resulted in the successful conclusion of the licensing deal with Avion Pharmaceuticals, our partner for Lupuzor™, which is now close to embarking on its international Phase 3 trial. His extensive pharmaceutical and capital markets experience will contribute enormously to the team as we look to move into the next phase of our journey for the Company.” said Board Chairman, Tim McCarthy.  

About Dr. Tim Franklin

Tim has worked with ImmuPharma for over three years, initially as a consultant and more recently was appointed as Chief Operating Officer in November 2020. Tim’s key responsibilities include working closely with ImmuPharma’s clinical team and scientific advisors, as the Company looks to further progress its wider drug development portfolio, both through clinical development and partnering opportunities.

In addition, Tim will lead the relationship with Avion Pharmaceuticals, as the Company advances Lupuzor through its Phase 3 trial and regulatory processes involved in the ultimate approval of the drug.

Tim has over 30 years of experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner-Lambert, Wellcome, and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital.

He holds a BSc in Medicinal Chemistry and a Ph.D. in Pharmacology from Loughborough University and an MBA from Warwick Business School.

About ImmuPharma PLC

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor, is a first-in-class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor to fund a new international Phase 3 trial for Lupuzor and commercialise in the US.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.